<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607746</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-CVI-5794</org_study_id>
    <nct_id>NCT04607746</nct_id>
  </id_info>
  <brief_title>Pivotal Study of the CapsoCam Colon (CV-3) in Detecting Colonic Polyps, Using Colonoscopy as the Reference</brief_title>
  <official_title>Prospective Open Label, Pivotal Study of the Accuracy of The CapsoCam Colon (CV-3) in Detecting Colonic Polyps, Using Colonoscopy as the Reference</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capso Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capso Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of the CapsoCam Colon (CV-3) endoscope&#xD;
      system for the detection of colonic polyps.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive Percent Agreement/Negative Percent Agreement</measure>
    <time_frame>6 weeks</time_frame>
    <description>Positive Percent Agreement (PPA) of CapsoCam® Colon (CV-3) for detecting the presence in a subject of the largest polyp detected by optical colonoscopy (OC) if that polyp is ≥ 6 mm Negative Percent Agreement (NPA) of the device for not detecting any polyp ≥ 6 mm in a subject for whom OC did not detect any polyp ≥ 6 mm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive Percent Agreement/Negative Percent Agreement--secondary</measure>
    <time_frame>6 weeks</time_frame>
    <description>PPA of the device for detecting the presence in a subject of the largest polyp detected by optical colonoscopy (OC) if that polyp is, ≥ 6 mm and &lt; 10 mm, or ≥ 10 mm (same matching rules) NPA of the device for not detecting any polyp ≥ 10 mm in a subject for whom OC did not detect any polyp ≥ 6 mm and &lt; 10 mm or ≥ 10 mm.&#xD;
PPA of the device for detecting the presence of a polyp ≥ 6 mm in a subject with OC as the reference (without regard to polyp matching).&#xD;
PPA of the device for detecting the presence in a subject of a polyp ≥ 6 mm and &lt; 10 mm with OC as the reference (without regard to polyp matching).&#xD;
PPA of the device for detecting the presence in a subject of the largest sessile serrated polyp detected by OC if that polyp is ≥ 6 mm, (same matching rules) PPA of the device for detecting the presence in a subject of a cancerous polyp biopsied by OC and diagnosed by histopathology, (same matching rules as above)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Colonic Polyp</condition>
  <arm_group>
    <arm_group_label>Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will swallow the capsule for imaging prior to completing colonoscopy. Capsule swallow may be 1 day prior or 3-6 weeks prior to colonoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Capsule Endoscope</intervention_name>
    <description>Capsule endoscope used to view colonic mucosa</description>
    <arm_group_label>Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 50-75 years of age&#xD;
&#xD;
          2. Committed to undergo a colonoscopy, independent of this study&#xD;
&#xD;
          3. Choose to participate and must have signed the IRB-approved informed consent document&#xD;
             and agreed to release colonoscopy images and results report to Sponsor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Colonoscopy or CT-colonography within the past 5 years that demonstrated no polyps&#xD;
&#xD;
          2. Has contraindication for capsule endoscopy or colonoscopy&#xD;
&#xD;
          3. Subject is suspected or diagnosed with familial adenomatous polyposis, hereditary non&#xD;
             polyposis colon cancer, or any high-risk genetic syndrome&#xD;
&#xD;
          4. Subject is suspected or diagnosed with inflammatory bowel disease such as ulcerative&#xD;
             colitis or Crohn's disease&#xD;
&#xD;
          5. History of incomplete colonoscopy&#xD;
&#xD;
          6. Type I or uncontrolled II Diabetes (HbA1C&gt;6.4 within the past 3 months) with a history&#xD;
             of constipation or gastroparesis.&#xD;
&#xD;
          7. Impaired cardiac function assessed as greater than NYHA Class II&#xD;
&#xD;
          8. History of small- or large-bowel obstructive condition&#xD;
&#xD;
          9. Known history of swallowing disorder, and/or ischemic bowel disease neuropathies&#xD;
             and/or radiation enteritis&#xD;
&#xD;
         10. Known history of NSAID enteropathy and stricture resulting from taking NSAIDs on a&#xD;
             regular basis that, in the opinion of the Investigator, would put the subject at&#xD;
             greater risk for capsule endoscope retention&#xD;
&#xD;
         11. Known allergy to ingredients used in bowel preparation and boosters&#xD;
&#xD;
         12. Daily and/or regular narcotic use&#xD;
&#xD;
         13. Uncompensated cirrhosis&#xD;
&#xD;
         14. Prior abdominal radiation therapy&#xD;
&#xD;
         15. Diagnosis of anorexia or bulimia&#xD;
&#xD;
         16. History of or suspicion of any of the following: strictures, volvulus or intestinal&#xD;
             obstruction, or internal hernias or abdominal surgeries that the Investigator believes&#xD;
             should exclude the patient from study participation&#xD;
&#xD;
         17. Known or suspected megacolon&#xD;
&#xD;
         18. Scheduled to undergo MRI examination within 7 days after ingestion of the capsule&#xD;
&#xD;
         19. Has known slow gastric-emptying time or confirmed diagnosis of gastroparesis&#xD;
&#xD;
         20. Pregnant or nursing or is of child-bearing potential and does not practice medically&#xD;
             acceptable methods of contraception. WOCBP must have a negative urine pregnancy test&#xD;
             at screening.&#xD;
&#xD;
         21. Unable to follow or tolerate fasting, bowel preparation, and other study procedures&#xD;
&#xD;
         22. Any documented medical or psychological condition or significant concurrent illness&#xD;
             which, in the Investigator's opinion, would make it unsafe for the subject to&#xD;
             participate in this research study or would affect the validity of the study results&#xD;
&#xD;
         23. Are currently enrolled in, or participated in within the last 30 days, another&#xD;
             clinical study&#xD;
&#xD;
         24. Chronic constipation as defined by &lt;3 bowel movements per week, or the use of routine&#xD;
             laxatives (other than fiber) to attain regular bowel movements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tammy Morton, MS</last_name>
    <phone>408-416-4137</phone>
    <email>tammy.morton@capsovision.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca Guzman</last_name>
    <phone>408-370-1940</phone>
    <email>rebecca.guzman@capsovision.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandria Evans</last_name>
      <email>alexandria.evans@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Leighton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>InSite Digestive Health Care</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northern California</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94577</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Mendelssohn</last_name>
      <phone>650-299-4165</phone>
    </contact>
    <investigator>
      <last_name>Sanja Garuda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Velazquez</last_name>
      <phone>727-835-3261</phone>
    </contact>
    <investigator>
      <last_name>Curtis Freedland, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Michigan Clinical Research Center</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rochelle Copeland</last_name>
      <phone>616-608-8730</phone>
    </contact>
    <investigator>
      <last_name>Allan Coates, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Lavey</last_name>
      <email>lavey.crystal@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Rajan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hattiesburg GI Associates</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clay Foley</last_name>
      <phone>601-268-5185</phone>
    </contact>
    <investigator>
      <last_name>Stephen Buckley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NY Total Medical Care</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Vilo Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants of SW Virginia</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darian Trojacek, MSc</last_name>
      <email>dtrojacek@roanokegastro.onmicrosoft.com</email>
    </contact>
    <investigator>
      <last_name>Nirish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vishal Bhagat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyps</mesh_term>
    <mesh_term>Colonic Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

